Notice2024-11549
Joint Biomedical Laboratory Research and Development and Clinical Science Research and Development Services Scientific Merit Review Board, Notice of Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 28, 2024
Issuing agencies
Veterans Affairs Department
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 103 (Tuesday, May 28, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 103 (Tuesday, May 28, 2024)]
[Notices]
[Page 46307]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-11549]
DEPARTMENT OF VETERANS AFFAIRS
Joint Biomedical Laboratory Research and Development and Clinical
Science Research and Development Services Scientific Merit Review
Board, Notice of Meeting
The Department of Veterans Affairs (VA) gives notice under the
Federal Advisory Committee Act, 5 U.S.C. Ch.10, that a meeting of the
Joint Biomedical Laboratory Research and Development and Clinical
Science Research and Development Services Scientific Merit Review Board
will be held July 9, 2024, via Webex. The meeting will be held between
3 p.m. and 5 p.m. EDT. The meeting will be closed to the public from
3:30-5 p.m. EDT for scientific review and the discussion, examination,
and reference to the research applications. Discussions will involve
reference to staff and consultant critiques of research proposals.
Discussions will deal with scientific merit of each proposal and
qualifications of personnel conducting the studies, the disclosure of
which would constitute a clearly unwarranted invasion of personal
privacy. Additionally, premature disclosure of research information
could significantly obstruct implementation of proposed agency action
regarding the research proposals. As provided by Public Law 92-463
subsection 10(d), as amended by Public Law 94-409, closing the
committee meeting is in accordance with 5 U.S.C. 552b(c)(6) and (9)(B).
The objective of the Board is to provide for the fair and equitable
selection of the most meritorious research projects for support by VA
research funds and to offer advice for research program officials on
program priorities and policies. The ultimate objective of the Board is
to ensure the high quality and mission relevance of VA's legislatively
mandated Biomedical Laboratory and Clinical Science Research and
Development programs.
Board members advise the Directors of the Biomedical Laboratory and
Clinical Sciences Research Services and the Chief Research and
Development Officer on the scientific and technical merit, the mission
relevance, and the protection of human subjects of Biomedical
Laboratory and Clinical Sciences Research and Development proposals.
The Board does not consider grants, contracts, or other forms of
extramural research.
Members of the public may attend the open portion of the meeting.
To attend the open portion of the meeting (3-3:30 p.m. EDT), the public
may join by dialing the phone number 1-404-397-1596 and entering the
meeting number (access code): 2820 097 2881. Public comments accepted
during the open portion of the meeting and Public stakeholders who want
to speak to the committee will be afforded 3 minutes during the public
comment period. These stakeholders must notify the DFO of their
intention to speak to the Committee.
Written public comments must be sent to Michael R. Burgio, Ph.D.,
Designated Federal Officer, Advisory Committee Management Office, 811
Vermont Avenue NW, Room 4342A, Washington, DC 20006, or to
<a href="/cdn-cgi/l/email-protection#763b1f151e17131a58340304111f1936001758111900"><span class="__cf_email__" data-cfemail="226f4b414a43474e0c605750454b4d6254430c454d54">[email protected]</span></a> at least five days before the meeting. The
written public comments will be shared with the board members. The
public may not attend the closed portion of the meeting as disclosure
of research information could significantly obstruct implementation of
proposed agency action regarding the research proposals (Public Law 92-
463 subsection 10(d), as amended by Public Law 94-409, closing the
committee meeting is in accordance with 5 U.S.C. 552b(c)(6) and (9)(B).
Dated: May 21, 2024.
LaTonya L. Small,
Federal Advisory Committee Management Officer.
[FR Doc. 2024-11549 Filed 5-24-24; 8:45 am]
BILLING CODE 8320-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 28, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.